Schizophrenia News

SAN FRANCISCO — SEP-363856, a novel psychotropic agent with a non-D2 mechanism of action, showed statistically significant and clinically meaningful symptom improvement in patients with schizophrenia, according to data from a 4-week study presented at the APA annual meeting.

SAN FRANCISCO — Post hoc analysis data presented at the APA annual meeting demonstrated that Vraylar, made by Allergan, may offer benefits for cognition symptoms in patients with schizophrenia.

Research published in American Journal of Psychiatry indicated that substance-induced psychotic disorder occurred in people at high familial risk for drug and alcohol abuse and a moderate familial vulnerability to psychosis.

The FDA has granted breakthrough therapy designation for SEP-363856, a novel agent for the treatment of people with schizophrenia, according to a press release.

Analysis published in American Journal of Psychiatry revealed that history of engaging in injurious violence in the 6 months before baseline assessment and recent violent victimization were the most powerful predictors of later injurious violent behavior in individuals with schizophrenia.

A Danish nationwide birth cohort study showed that the incidence rates of any mental disorder, substance use disorders, depression and anxiety disorders increased substantially by adolescence.

Offspring born to couples in sexual contact for less than 3 years before conceiving them may be at a slightly increased risk for schizophrenia, study findings showed.

Lay health supporters aided by a mobile text messaging intervention led to improvements in medication adherence, relapses and rehospitalizations among people with schizophrenia in a resource-poor community in rural China, according to a PLOS Medicine study.

Patients with schizophrenia treated with ALKS 3831, a combination of olanzapine and samidorphan, had less weight gain than those treated with olanzapine alone, according to a presentation from the 2019 Congress of the Schizophrenia International Research Society.

In a viewpoint published in JAMA Psychiatry, experts from Columbia University wrote that placebo-controlled, relapse prevention studies for schizophrenia should no longer be conducted; instead, trials should use active comparators that would protect patients from relapse and offer data on the comparative effectiveness of the drugs involved.